Vericel opened higher at $59.50, compared with its previous close of $59.45. In the last trading session, the stock traded between $56.92 and $59.50. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Vericel is now worth
$ 134.73
Giving a profit of
$ 34.73 (34.73%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
$-2.08 (-3.50%)
Day High
$59.50
Day Low
$56.92
Day Open
$59.50
Prev Close
$59.45
Volume
6,22,840
1W Return
26.15%
1M Return
41.20%
3M Return
29.47%
6M Return
74.27%
1Y Return
39.76%
Fundamentals
Market Cap ($ Mn)
2,928
PE Ratio
87.15
PB Ratio
5.66
PEG Ratio
4.68
ROE
5.26%
ROCE
2.74%
EPS (TTM)
$0.28
Investment Returns
1 Week
26.15%
1 Month
41.20%
3 Months
29.47%
6 Months
74.27%
9 Months
65.67%
Financials
Quarterly
All values in $ Mn
63.2
Jun 25
67.5
Sep 25
92.9
Dec 25
68.4
Mar 26
77.5
Jun 26
85.4
Sep 26
Updates
10Nov
Stephens raises Vericel price target to $68; maintains Overweight
Stephens & Co. raised Vericel's price target to $68 from $55. Analyst Mason Carrico maintained an Overweight rating on the stock. Recent revisions by HC Wainwright ($75) and Truist ($65) show rising consensus. All three firms maintain positive ratings (Buy or Overweight) on Vericel.
2 days ago
30Jul
Vericel raises FY26 revenue guidance to $330-340M, beats estimates
Vericel Corporation reported Q2 2026 net income of $2.2 million and raised full-year revenue guidance to $330-340 million, exceeding analyst estimates. Strong MACI and Burn Care sales drove 22% revenue growth.
3mo ago
17Jul
Truist Securities raises Vericel price target to $54
Truist Securities analyst Richard Newitter maintained a Buy rating on Vericel and increased the price target from $42 to $54.
